INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567894, 'Botulinum toxin type B', 'Netilmicin', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567895, 'Botulinum toxin type B', 'Botulinum toxin type A', 'Moderate', 'The effect of administering different botulinum neurotoxin serotypes concurrently or within several months of one another is unknown.  Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567896, 'Botulinum toxin type B', 'Pancuronium', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567897, 'Botulinum toxin type B', 'Phenindamine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567898, 'Botulinum toxin type B', 'Pimozide', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567899, 'Botulinum toxin type B', 'Pipecuronium', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567900, 'Botulinum toxin type B', 'Polymyxin B', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567901, 'Botulinum toxin type B', 'Promazine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567902, 'Botulinum toxin type B', 'Propiomazine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567903, 'Botulinum toxin type B', 'Mepyramine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567904, 'Botulinum toxin type B', 'Rapacuronium', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567905, 'Botulinum toxin type B', 'Solifenacin', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567906, 'Botulinum toxin type B', 'Spectinomycin', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567907, 'Botulinum toxin type B', 'Triflupromazine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567908, 'Alimemazine', 'Botulinum toxin type B', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567909, 'Botulinum toxin type B', 'Tripelennamine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567910, 'Botulinum toxin type B', 'Triprolidine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567911, 'Botulinum toxin type B', 'Tubocurarine', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567912, 'Botulinum toxin type B', 'Vecuronium', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567913, 'Acrivastine', 'Primidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567914, 'Primidone', 'Phenylbutyric acid', 'Moderate', 'Drugs that can increase plasma ammonia levels such as corticosteroids, haloperidol, or the anticonvulsants carbamazepine, topiramate, and phenobarbital may interfere with the therapeutic effects of phenylbutyrate therapy in the management of urea cycle disorders.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567915, 'Valganciclovir', 'Promazine', 'Moderate', 'The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney.', NULL, 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.', NULL, 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.  Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa.  If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567916, 'Acrivastine', 'Valerian', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567917, 'Botulinum toxin type A', 'Triprolidine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567918, 'Botulinum toxin type A', 'Vecuronium', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567919, 'Vinblastine', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567920, 'Vinblastine', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567921, 'Anisindione', 'Cefradine', 'Moderate', 'Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists.  Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.', NULL, 'Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.', NULL, 'Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.  The anticoagulant dose may be adjusted as indicated.  Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567922, 'Cefradine', 'Bifidobacterium longum infantis', 'Moderate', 'Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.', NULL, 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', NULL, 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567923, 'Dicoumarol', 'Cefradine', 'Moderate', 'Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists.  Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.', NULL, 'Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.', NULL, 'Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.  The anticoagulant dose may be adjusted as indicated.  Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567924, 'Cefradine', 'Netilmicin', 'Moderate', 'Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity.  An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone).', NULL, 'The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.', NULL, 'The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.  Renal function should be monitored closely.  The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567925, 'Venetoclax', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567926, 'Venetoclax', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567927, 'Botulinum toxin type A', 'Solifenacin', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567928, 'Cefazolin', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567929, 'Cefepime', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567930, 'Cefotaxime', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567931, 'Ifosfamide', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567932, 'Telavancin', 'Netilmicin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567933, 'Telavancin', 'Polymyxin B', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567934, 'Uracil mustard', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567935, 'Acrivastine', 'Vigabatrin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567936, 'Chlorcyclizine', 'Vigabatrin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567937, 'Vigabatrin', 'Risdiplam', 'Moderate', 'Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity.', NULL, 'Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.', NULL, 'Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.  These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567938, 'Vincristine', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567939, 'Vincristine', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567940, 'Vinorelbine', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567941, 'Vinorelbine', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567942, 'Rofecoxib', 'Acetohexamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567943, 'Anisindione', 'Rofecoxib', 'Moderate', 'Rofecoxib may potentiate the hypoprothrombinemic effect of warfarin and other oral anticoagulants as determined by the INR.', NULL, 'Patients should be closely monitored during concomitant therapy with oral anticoagulants and rofecoxib.', NULL, 'Patients should be closely monitored during concomitant therapy with oral anticoagulants and rofecoxib.  The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of rofecoxib in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567944, 'Anistreplase', 'Rofecoxib', 'Moderate', 'Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.', NULL, 'Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.', NULL, 'Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.  Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567945, 'Bendroflumethiazide', 'Rofecoxib', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states.  The risk may be increased in patients on dietary sodium restriction.  At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure.  Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.  If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567946, 'Benzthiazide', 'Rofecoxib', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states.  The risk may be increased in patients on dietary sodium restriction.  At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure.  Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.  If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567947, 'Bromfenac', 'Rofecoxib', 'Major', 'Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation.', NULL, 'Concomitant use of COX-2 inhibitors with non-aspirin NSAIDs should generally be avoided.', NULL, 'Concomitant use of COX-2 inhibitors with non-aspirin NSAIDs should generally be avoided.  Some authorities consider this combination to be contraindicated due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (AU,UK).', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567948, 'Dicoumarol', 'Rofecoxib', 'Moderate', 'Rofecoxib may potentiate the hypoprothrombinemic effect of warfarin and other oral anticoagulants as determined by the INR.', NULL, 'Patients should be closely monitored during concomitant therapy with oral anticoagulants and rofecoxib.', NULL, 'Patients should be closely monitored during concomitant therapy with oral anticoagulants and rofecoxib.  The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of rofecoxib in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567949, 'Enoxacin', 'Rofecoxib', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567950, 'Grepafloxacin', 'Rofecoxib', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567951, 'Iodipamide', 'Rofecoxib', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567952, 'Rofecoxib', 'Levobupivacaine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567953, 'Rofecoxib', 'Lomefloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567954, 'Rofecoxib', 'Methoxyflurane', 'Moderate', 'Coadministration of methoxyflurane with other nephrotoxic agents may increase the risk of renal impairment.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567955, 'Rofecoxib', 'Netilmicin', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.', NULL, 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.', NULL, 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567956, 'Rofecoxib', 'Oxtriphylline', 'Moderate', 'The coadministration with rofecoxib may increase the plasma concentrations of theophylline.  The proposed mechanism is rofecoxib inhibition of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of theophylline.', NULL, 'Caution is advised during coadministration of theophylline with rofecoxib.', NULL, 'Caution is advised during coadministration of theophylline with rofecoxib.  Theophylline plasma levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of rofecoxib therapy in patients who are stabilized on their theophylline regimen.  Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567957, 'Rofecoxib', 'Phenylbutazone', 'Major', 'Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation.', NULL, 'Concomitant use of COX-2 inhibitors with non-aspirin NSAIDs should generally be avoided.', NULL, 'Concomitant use of COX-2 inhibitors with non-aspirin NSAIDs should generally be avoided.  Some authorities consider this combination to be contraindicated due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (AU,UK).', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567958, 'Trichlormethiazide', 'Rofecoxib', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states.  The risk may be increased in patients on dietary sodium restriction.  At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure.  Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.  If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567959, 'Perampanel', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567960, 'Bacillus calmette-guerin substrain tice live antigen', 'Pegaspargase', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567961, 'Pegaspargase', 'Onasemnogene abeparvovec', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins).  Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs.  Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567962, 'Varicella Zoster Vaccine (Recombinant)', 'Pegaspargase', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567963, 'Acrivastine', 'Opicapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567964, 'Acrivastine', 'Opium', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567965, 'Botulinum toxin type A', 'Pimozide', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567966, 'Thiopental', 'Pimozide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567967, 'Ethotoin', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567968, 'Peginterferon beta-1a', 'Pegloticase', 'Moderate', 'Antibodies that develop during pegloticase therapy may theoretically affect the pharmacologic effects of other pegylated agents.', NULL, 'Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.', NULL, 'Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567969, 'Acrivastine', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567970, 'Anisindione', 'Thiopental', 'Major', 'Barbiturates reduce the effects of oral anticoagulants by inducing their hepatic metabolism.', NULL, 'Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued.', NULL, 'Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued.  Alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate.  Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567971, 'Chloral hydrate', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567972, 'Chlorcyclizine', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567973, 'Chlormezanone', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567974, 'Chlorphenesin', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567975, 'Cyclizine', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567976, 'Dezocine', 'Thiopental', 'Moderate', 'Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567977, 'Dicoumarol', 'Thiopental', 'Major', 'Barbiturates reduce the effects of oral anticoagulants by inducing their hepatic metabolism.', NULL, 'Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued.', NULL, 'Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued.  Alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate.  Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567978, 'Digitoxin', 'Thiopental', 'Moderate', 'Barbiturates may decrease serum digitoxin levels, possibly by increasing hepatic conversion of digitoxin to digoxin.  Phenobarbital is the only barbiturate specifically implicated in this interaction.  However, other barbiturates may behave in a similar fashion.', NULL, 'Close observation for clinical and laboratory evidence of altered digitoxin effect is indicated if a barbiturate and digitoxin must be used together.', NULL, 'Close observation for clinical and laboratory evidence of altered digitoxin effect is indicated if a barbiturate and digitoxin must be used together.  Digoxin is not expected to be affected to the same extent.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567979, 'Halazepam', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567980, 'Diamorphine', 'Thiopental', 'Moderate', 'Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567981, 'Thiopental', 'Levacetylmethadol', 'Moderate', 'Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', NULL, 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567982, 'Thiopental', 'Methdilazine', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567983, 'Thiopental', 'Methotrimeprazine', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567984, 'Thiopental', 'Methoxyflurane', 'Moderate', 'Barbiturates may increase risk of methoxyflurane-induced nephrotoxicity.  Laboratory and animal studies have demonstrated that barbiturates increase the metabolism of methoxyflurane to nephrotoxic metabolities (particularly inorganic fluoride), probably by CYP450 induction.', NULL, 'Methoxyflurane should generally not be administered to patients receiving barbiturates concurrently and for several weeks after barbiturates have been discontinued.', NULL, 'Methoxyflurane should generally not be administered to patients receiving barbiturates concurrently and for several weeks after barbiturates have been discontinued.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567985, 'Thiopental', 'Oxtriphylline', 'Moderate', 'Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines.  The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.', NULL, 'Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.', NULL, 'Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.  Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567986, 'Thiopental', 'Paramethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567987, 'Thiopental', 'Phenacemide', 'Minor', 'A study with ethylphenacemide has suggested that phenacemide may increase serum levels of barbiturates.  The mechanism is unknown.', NULL, 'The combination of ethylphenacemide and barbiturates is not clinically frequent and their concomitant use is generally not recommended.', NULL, 'The combination of ethylphenacemide and barbiturates is not clinically frequent and their concomitant use is generally not recommended.', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567988, 'Thiopental', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567989, 'Thiopental', 'Phensuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567990, 'Thiopental', 'Promazine', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567991, 'Thiopental', 'Propiomazine', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567992, 'Thiopental', 'Sulfamethizole', 'Minor', 'Some sulfonamides may enhance the effects of thiopental.  Mental depression and anesthesia may be increased.', NULL, 'Management consists of monitoring respiratory and clinical status during therapy.', NULL, 'Management consists of monitoring respiratory and clinical status during therapy.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567993, 'Triflupromazine', 'Thiopental', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567994, 'Alimemazine', 'Thiopental', 'Minor', 'Limited evidence suggests that phenothiazines may increase neuromuscular excitation and hypotension in patients receiving barbiturate anesthetics.', NULL, 'Caution should be exercised if these agents must be used together.', NULL, 'Caution should be exercised if these agents must be used together.  Patients should be monitored for altered effects.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567995, 'Tripelennamine', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567996, 'Acrivastine', 'Perampanel', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567997, 'Chlorcyclizine', 'Perampanel', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567998, 'Perampanel', 'Lesinurad', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1567999, 'Somatrem', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568000, 'Troglitazone', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568001, 'Acrivastine', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568002, 'Chlorcyclizine', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568003, 'Abarelix', 'Astemizole', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568004, 'Abarelix', 'Bepridil', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568005, 'Grepafloxacin', 'Abarelix', 'Major', 'Grepafloxacin can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568006, 'Isoetharine', 'Abarelix', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568007, 'Abarelix', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568008, 'Abarelix', 'Lomefloxacin', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568009, 'Abarelix', 'Methotrimeprazine', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568010, 'Abarelix', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568011, 'Abarelix', 'Promazine', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568012, 'Abarelix', 'Triflupromazine', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568013, 'Alimemazine', 'Abarelix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568014, 'Bacillus calmette-guerin substrain tice live antigen', 'Plicamycin', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568015, 'Bifidobacterium longum infantis', 'Plicamycin', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568016, 'Candida albicans', 'Plicamycin', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568017, 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Plicamycin', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568018, 'Coccidioides immitis spherule', 'Plicamycin', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568019, 'Dexfenfluramine', 'Plicamycin', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568020, 'Enoxacin', 'Plicamycin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568021, 'Grepafloxacin', 'Plicamycin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568022, 'Plicamycin', 'Lomefloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', NULL, 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568023, 'Tositumomab', 'Plicamycin', 'Major', 'Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.  Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.  A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for a minimum of 10 weeks after treatment.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568024, 'Varicella Zoster Vaccine (Recombinant)', 'Plicamycin', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568025, 'Bacillus calmette-guerin substrain tice live antigen', 'Polatuzumab vedotin', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568026, 'Varicella Zoster Vaccine (Recombinant)', 'Polatuzumab vedotin', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568027, 'Cefamandole', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568028, 'Cefazolin', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568029, 'Cefepime', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568030, 'Cefotaxime', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568031, 'Cefoxitin', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568032, 'Ifosfamide', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568033, 'Polymyxin B', 'Methoxyflurane', 'Moderate', 'Coadministration of methoxyflurane with other nephrotoxic agents may increase the risk of renal impairment.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568034, 'Botulinum toxin type A', 'Polymyxin B', 'Major', 'The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.', NULL, 'Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568035, 'Sulfamethoxazole', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568036, 'Uracil mustard', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568037, 'Bacillus calmette-guerin substrain tice live antigen', 'Pomalidomide', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568038, 'Varicella Zoster Vaccine (Recombinant)', 'Pomalidomide', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568039, 'Deserpidine', 'Oxitriptan', 'Moderate', 'Rauwolfia alkaloids such as reserpine may potentiate the pharmacologic effects of 5-hydroxytryptophan, which is converted to 5-hydroxytryptamine (5-HT), or serotonin, in vivo.  Rauwolfia alkaloids deplete catecholamine and serotonin stores in many organs, thus use of these agents may sensitize peripheral and central 5-HT receptors to serotonin.', NULL, 'Alternatives to rauwolfia alkaloids should be considered for treatment of hypertension in patients treated with 5-hydroxytryptophan.', NULL, 'Alternatives to rauwolfia alkaloids should be considered for treatment of hypertension in patients treated with 5-hydroxytryptophan.  If the combination is used, close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568040, 'Dexfenfluramine', 'Oxitriptan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.', NULL, 'The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568041, 'Dezocine', 'Oxitriptan', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.', NULL, 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', NULL, 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568042, 'Oxitriptan', 'Levacetylmethadol', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.', NULL, 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', NULL, 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568043, 'Brentuximab vedotin', 'Lamivudine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568044, 'Brentuximab vedotin', 'Abacavir', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568045, 'Abacavir', 'Ketoconazole', 'Major', 'Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568046, 'Dolutegravir', 'Somapacitan', 'Minor', 'Coadministration with inducers of UGT1A and CYP450 3A4 isoenzymes may decrease the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4.  Dolutegravir is also a substrate of UGT1A3, UGT1A9, and P-glycoprotein in vitro.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution may be advisable if dolutegravir is used in combination with mild or moderate UGT1A/CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution may be advisable if dolutegravir is used in combination with mild or moderate UGT1A/CYP450 3A4 inducers.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568047, 'Dolutegravir', 'St. John''s Wort', 'Major', 'Coadministration with potent inducers of UGT1A1 and CYP450 3A4 isoenzymes may significantly decrease the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4.  Dolutegravir is also a substrate of UGT1A3, UGT1A9, and P-glycoprotein in vitro.', NULL, 'In patients with HIV-1 without integrase inhibitor (INI) resistance, some authorities recommend a dolutegravir dose of 50 mg twice daily for both adults and pediatric patients 12 years of age and older who weigh at least 40 kg when coadministered with potent UGT1A1 and CYP450 3A4 inducers including carbamazepine, phenytoin, phenobarbital, and St.', NULL, 'In patients with HIV-1 without integrase inhibitor (INI) resistance, some authorities recommend a dolutegravir dose of 50 mg twice daily for both adults and pediatric patients 12 years of age and older who weigh at least 40 kg when coadministered with potent UGT1A1 and CYP450 3A4 inducers including carbamazepine, phenytoin, phenobarbital, and St. John''s Wort.  However, other authorities advise that coadministration of dolutegravir with these inducers should be avoided.  The safety and efficacy of dosages above 50 mg twice daily have not been evaluated.  Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible for INI-experienced patients with certain INI-associated resistance substitutions or clinically suspected INI resistance.  In addition, concomitant use of potent UGT1A1 and CYP450 3A4 inducers with fixed-dose combination products containing dolutegravir is not recommended; however, when used in combination with carbamazepine, some authorities advise administration of an additional 50 mg daily dose of dolutegravir approximately 12 hours from the combination product.  Local antiretroviral treatment experts should be consulted for current practice.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568048, 'Brentuximab vedotin', 'Zidovudine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568049, 'Gemtuzumab ozogamicin', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity.', NULL, 'Hematological parameters should be closely monitored.', NULL, 'Hematological parameters should be closely monitored.  Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568050, 'Ibritumomab tiuxetan', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity.', NULL, 'Hematological parameters should be closely monitored.', NULL, 'Hematological parameters should be closely monitored.  Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568051, 'Zidovudine', 'Ketoconazole', 'Major', 'Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568052, 'Zidovudine', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568053, 'Zidovudine', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568054, 'Diamorphine', 'Dextromethorphan', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568055, 'Dextromethorphan', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568056, 'Emtricitabine', 'Brentuximab vedotin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568057, 'Emtricitabine', 'Ketoconazole', 'Major', 'Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568058, 'Abametapir (topical)', 'Lopinavir', 'Moderate', 'Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations.', NULL, 'Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.', NULL, 'Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.  If this is not feasible, the manufacturer recommends avoiding use of abametapir lotion.  If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568059, 'Abarelix', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568060, 'Abiraterone', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568061, 'Acarbose', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568062, 'Acebutolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568063, 'Acetohexamide', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568064, 'Adenosine', 'Lopinavir', 'Moderate', 'Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome.  Theoretically, coadministration of adenosine with agents that can prolong the QT interval may increase that risk as well.  The mechanism has not been established, but may involve the depressant effect of adenosine on the sinoatrial and atrioventricular nodes.', NULL, 'Adenosine should be used with caution in patients receiving drugs that may prolong the QT interval.', NULL, 'Adenosine should be used with caution in patients receiving drugs that may prolong the QT interval.  Adenosine should be discontinued immediately if severe bradycardia occurs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568065, 'Albiglutide', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568066, 'Salbutamol', 'Lopinavir', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568067, 'Alectinib', 'Lopinavir', 'Moderate', 'Coadministration of alectinib with other agents that can slow the heart rate may increase the risk of bradycardia.', NULL, 'Caution is advised when alectinib is prescribed with other drugs that can cause bradycardia (e.', NULL, 'Caution is advised when alectinib is prescribed with other drugs that can cause bradycardia (e.g., beta-blockers; calcium channel blockers; digitalis; dolasetron; flecainide; ivabradine; lacosamide; mefloquine; moricizine; propafenone; quinine; succinylcholine; sunitinib; thalidomide; anticholinesterase or cholinergic agents; protease inhibitors such as atazanavir, lopinavir/ritonavir, and saquinavir/ritonavir).  Heart rate and blood pressure should be monitored regularly, and patients should be counseled to seek medical attention if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.  Dosage modification of alectinib is not required in cases of asymptomatic bradycardia.  However, if symptomatic bradycardia occurs, the manufacturer recommends withholding alectinib until recovery to asymptomatic bradycardia or to a heart rate of >=60 bpm.  Evaluate concomitant medications known to cause bradycardia and all antihypertensive medications, then consider dosage adjustments or discontinuation of concomitant medication(s) or alectinib in accordance with the product labeling.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568068, 'Alfuzosin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568069, 'Alogliptin', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568070, 'Aminoglutethimide', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568071, 'Amiodarone', 'Lopinavir', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568072, 'Amisulpride', 'Lopinavir', 'Major', 'Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and close clinical monitoring (e.', NULL, 'Caution and close clinical monitoring (e.g., electrocardiogram, serum electrolytes) are recommended if amisulpride is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568073, 'Amitriptyline', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568074, 'Amlodipine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568075, 'Amobarbital', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568076, 'Amoxapine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568077, 'Amprenavir', 'Lopinavir', 'Major', 'Coadministration with amprenavir may decrease the plasma concentrations of lopinavir, even in the presence of low-dose ritonavir as a pharmacokinetic booster.  The proposed mechanism is amprenavir induction of lopinavir metabolism via CYP450 3A4.', NULL, 'A dosage increase is recommended for lopinavir-ritonavir when used in combination with amprenavir.', NULL, 'A dosage increase is recommended for lopinavir-ritonavir when used in combination with amprenavir.  For adults, the dosage should be increased to 500 mg-125 mg (two 200 mg-50 mg tablets and one 100 mg-25 mg tablet) twice daily for the tablets and 533 mg-133 mg (6.5 mL) twice daily for the oral solution.  Lopinavir-ritonavir should not be administered as a once daily regimen in combination with amprenavir.  For pediatric patients 6 months to 18 years of age, the dosage should be increased to 300 mg-75 mg/m2 twice daily for the oral solution in both treatment-naive and treatment-experienced patients, not to exceed the recommended adult dosage of 533 mg-133 mg (6.5 mL) twice daily.  If weight-based dosing is preferred, the recommended dosage is 13 mg-3.25 mg/kg given twice daily for patients under 15 kg and 11 mg-2.75 mg/kg given twice daily for patients 15 kg to 45 kg.  Pediatric patients weighing more than 45 kg should receive the adult dosage of lopinavir-ritonavir.  Please consult the manufacturer''s product labeling for pediatric dosing of the tablet formulation.  Lopinavir-ritonavir should not be administered in combination with amprenavir in patients under 6 months of age due to the lack of clinical data.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568078, 'Anagrelide', 'Lopinavir', 'Major', 'Anagrelide can cause dose-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided.  Patients receiving anagrelide should have a cardiovascular examination, including an ECG, prior to initiation of treatment and monitored for cardiovascular effects during treatment.  Hypokalemia or hypomagnesemia must be corrected prior to therapy and electrolytes monitored periodically during therapy.  Anagrelide should not be used in the presence of known risk factors for QT interval prolongation such as congenital long QT syndrome or a history of acquired QTc prolongation.  Periodic electrocardiograms are recommended in patients with heart failure, bradyarrhythmias, or electrolyte abnormalities.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568079, 'Lopinavir', 'Apalutamide', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568080, 'Apomorphine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568081, 'Aprepitant', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568082, 'Arformoterol', 'Lopinavir', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568083, 'Aripiprazole', 'Lopinavir', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.  ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568084, 'Armodafinil', 'Lopinavir', 'Moderate', 'Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of protease inhibitors (PIs).  The mechanism involves induction of intestinal CYP450 3A4-mediated first-pass metabolism by modafinil and armodafinil, with possible secondary induction of hepatic 3A4 metabolism.  Significant intestinal metabolism appears to occur with indinavir and saquinavir but has not been studied with other PIs.  Conversely, PIs may increase the plasma concentrations of modafinil via inhibition of hepatic CYP450 3A4 metabolism.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with decreased or subtherapeutic antiretroviral drug levels, caution is advised if modafinil or armodafinil must be used in patients treated with PIs, particularly if they are using only one PI in their antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with decreased or subtherapeutic antiretroviral drug levels, caution is advised if modafinil or armodafinil must be used in patients treated with PIs, particularly if they are using only one PI in their antiretroviral regimen.  Clinical monitoring for altered effects of both modafinil and the PI may be appropriate following addition or withdrawal of one or the other drug.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568085, 'Arsenic trioxide', 'Lopinavir', 'Major', 'Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy.', NULL, 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy.  Caution is advised if concomitant use cannot be avoided.  Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged.  An absolute QT interval exceeding 500 msec will require immediate action to correct concomitant risk factors, if any, as well as a thorough assessment of the need for continued therapy.  Patients who develop syncope or arrhythmia should be hospitalized for clinical and laboratory monitoring.  Arsenic trioxide should be temporarily discontinued until symptoms resolve, the QTc interval regresses to below 460 msec, and electrolyte abnormalities are corrected.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568086, 'Asenapine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568087, 'Atazanavir', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568088, 'Atenolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568089, 'Atomoxetine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568090, 'Azithromycin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568091, 'Bedaquiline', 'Lopinavir', 'Major', 'Bedaquiline can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.  ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling.  Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.  All QT-prolonging drugs including bedaquiline should be interrupted in patients who develop clinically significant ventricular arrhythmia or a QTcF interval greater than 500 msec confirmed by repeat ECG.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568092, 'Bepridil', 'Lopinavir', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568093, 'Berotralstat', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568094, 'Betaxolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568095, 'Bexarotene', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568096, 'Bicalutamide', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568097, 'Bisacodyl', 'Lopinavir', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568098, 'Bisoprolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568099, 'Boceprevir', 'Lopinavir', 'Major', 'Coadministration of boceprevir with cobicistat-boosted or ritonavir-boosted regimens of atazanavir, darunavir, or lopinavir may result in decreased plasma concentrations of both boceprevir and the protease inhibitors.  The mechanism of interaction has not been described.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, the use of boceprevir in combination with ritonavir-boosted or cobicistat-boosted regimens of atazanavir, darunavir, or lopinavir is not recommended.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, the use of boceprevir in combination with ritonavir-boosted or cobicistat-boosted regimens of atazanavir, darunavir, or lopinavir is not recommended.  Moreover, the safety and efficacy of boceprevir has not been established in the HCV/HIV coinfected population.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568100, 'Bosentan', 'Lopinavir', 'Moderate', 'Coadministration of a protease inhibitor (PI) in combination with bosentan may increase the plasma concentration of bosentan and decrease that of the PI, unless ritonavir is included as a pharmacokinetic booster.  Both PIs and bosentan are primarily metabolized by CYP450 3A4.  Because PIs are also inhibitors of CYP450 3A4, they can inhibit the metabolic clearance of bosentan.  Conversely, bosentan may induce the metabolism of PIs, although the effects are probably not significant in the presence of ritonavir, which is a potent CYP450 3A4 inhibitor.', NULL, 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster.', NULL, 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster.  Dose adjustment of bosentan has been recommended.  In patients who are starting bosentan and have been receiving PI therapy for at least 10 days, it has been recommended to start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.  When starting PI therapy in patients already on bosentan, it has been recommended to discontinue bosentan for at least 36 hours prior to initiation of PI therapy.  After at least 10 days following the initiation of PI therapy, bosentan may be resumed at 62.5 mg once daily or every other day based upon individual tolerability.  According to some authorities, use of the fixed combination atazanavir-cobicistat with bosentan is not recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568101, 'Bosutinib', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568102, 'Brentuximab vedotin', 'Ritonavir', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.  MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568103, 'Brigatinib', 'Lopinavir', 'Moderate', 'Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever brigatinib is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568104, 'Buprenorphine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568105, 'Butabarbital', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568106, 'Butalbital', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568107, 'Cabozantinib', 'Lopinavir', 'Major', 'Cabozantinib can cause prolongation of the QT interval.Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568108, 'Canagliflozin', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568109, 'Carbamazepine', 'Lopinavir', 'Major', 'Coadministration of lopinavir-ritonavir with carbamazepine may result in decreased plasma concentrations of lopinavir and increased plasma concentrations of carbamazepine.  The proposed mechanism involves carbamazepine induction of lopinavir metabolism via CYP450 3A4 and conversely, lopinavir-ritonavir inhibition of carbamazepine metabolism via the same enzymatic pathway.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with carbamazepine.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with carbamazepine.  Once-daily administration of lopinavir-ritonavir should be avoided when used concomitantly with carbamazepine.  An increase in the dosage of lopinavir-ritonavir may be necessary, although dosage adjustment has not been evaluated in clinical studies.  Close clinical and laboratory monitoring of antiretroviral response is recommended following the addition or discontinuation of carbamazepine in patients already receiving lopinavir-ritonavir as part of their HIV treatment regimen.  Likewise, if lopinavir-ritonavir is added to stable carbamazepine therapy, serum drug levels and pharmacologic effects should be closely monitored and the carbamazepine dose adjusted accordingly.  Patients should be advised to contact their doctor if they develop signs of carbamazepine toxicity such as ataxia, disorientation, dizziness, nausea, vomiting, and visual disturbances.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568110, 'Carteolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568111, 'Carvedilol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568112, 'Frangula purshiana bark', 'Lopinavir', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568113, 'Castor oil', 'Lopinavir', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568114, 'Cenobamate', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568115, 'Ceritinib', 'Lopinavir', 'Major', 'Ceritinib can cause concentration-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.  ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.  Ceritinib should not be started if baseline QTc is greater than 500 msec.  Likewise, treatment should be withheld in patients who develop a QTc interval greater than 500 msec on at least 2 separate ECGs until the QTc interval is less than 481 msec or recovery to baseline (if the QTc interval is greater than or equal to 481 msec), then resume ceritinib with a 150 mg dosage reduction.  Permanently discontinue ceritinib therapy if QTc prolongation develops in combination with torsade de pointes or polymorphic ventricular tachycardia or signs and symptoms of serious arrhythmia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568116, 'Chloramphenicol', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568117, 'Chloroquine', 'Lopinavir', 'Major', 'Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.', NULL, 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome.  Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks.  Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568118, 'Chlorpromazine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568119, 'Chlorpropamide', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568120, 'Cilostazol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568121, 'Cimetidine', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568122, 'Ciprofloxacin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568123, 'Cisapride', 'Lopinavir', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568124, 'Citalopram', 'Lopinavir', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.  Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.  However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression.  A maximum dosage of 20 mg/day is recommended for patients with hepatic impairment, those greater than 60 years of age, and poor metabolizers of CYP450 2C19.  Patients at risk for significant electrolyte disturbances should have serum potassium and magnesium assessed at baseline and periodically during treatment.  If hypokalemia or hypomagnesemia is found, it should be corrected prior to initiation of treatment.  Regular ECG monitoring is also recommended, and persistent QTc measurements greater than 500 msec should prompt discontinuation of the medication.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  When citalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568125, 'Clarithromycin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568126, 'Clevidipine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568127, 'Clofazimine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568128, 'Clomipramine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568129, 'Clotrimazole', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568130, 'Clozapine', 'Lopinavir', 'Major', 'Clozapine has the potential to prolong QT interval of the electrocardiogram.  Theoretically, coadministration with other agents that can cause QT prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if clozapine is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if clozapine is used in combination with other drugs that can prolong the QT interval.  Serum electrolytes, including potassium, magnesium and calcium, should be measured at baseline and periodically during treatment, and any abnormalities corrected prior to initiating clozapine.  Routine ECG assessment may detect QTc prolongation, but is not always effective in preventing arrhythmias.  Clozapine treatment should be discontinued if the QTc interval exceeds 500 msec.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  Additional precaution is required when using QT-prolonging agents with anticholinergic properties, particularly in the elderly and those with underlying organic brain disease.  Patients should be advised to notify their physician if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Dosage adjustments may be necessary if excessive adverse effects develop.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568131, 'Cobicistat', 'Lopinavir', 'Moderate', 'Cobicistat may increase the plasma concentrations of antiretroviral agents.  The plasma concentrations of cobicistat may also be increased or reduced in the presence of antiretroviral agents.  The proposed mechanism is cobicistat inhibition of the CYP450 3A4 isoenzyme, of which antiretroviral agents may be substrates, and the inhibition or induction of CYP450 3A4 by concomitant antiretroviral medications.  Cobicistat is a mechanism-based inhibitor and substrate of CYP450 3A4 with no antiretroviral activity of its own.  Rather, it is indicated in its capacity as a pharmacokinetic booster of CYP450 3A4 to increase the systemic exposure of some antiretroviral medications such as atazanavir, darunavir, and elvitegravir, which are substrates of this isoenzyme.  Concomitant use of other antiretroviral agents with cobicistat may also increase the plasma levels and risk of side effects associated with these medicines.  In contrast, concomitant use of cobicistat-boosted atazanavir or darunavir with CYP450 3A4 inducers nevirapine, etravirine, or efavirenz may reduce the plasma concentrations of cobicistat, darunavir, and atazanavir, leading to a potential loss of therapeutic effect and development of resistance to darunavir and atazanavir.  Pharmacokinetic data are not available.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor.  In addition, cobicistat should not be used concomitantly with ritonavir due to their similar effects on CYP450 3A4.  According to some authorities, use of the antiretroviral combinations of atazanavir-cobicistat or darunavir-cobicistat concomitantly with the CYP450 3A4 inducers efavirenz, etravirine, or nevirapine is also not recommended.  Other authorities consider the administration of atazanavir-cobicistat with efavirenz or nevirapine to be contraindicated.  Since dosing recommendations have only been established for a number of antiretroviral medications, product labeling and current antiretroviral treatment guidelines should be consulted.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568132, 'Conivaptan', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568133, 'Crizotinib', 'Lopinavir', 'Major', 'Crizotinib can cause concentration-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if crizotinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if crizotinib is used in combination with other drugs that can prolong the QT interval.  ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting crizotinib therapy and periodically during treatment.  Crizotinib should not be started if baseline QTc is greater than 500 msec.  Likewise, treatment should be interrupted in patients who develop Grade 3 QTc prolongation until recovery to less than or equal to Grade 1, then resumed at 200 mg twice daily.  In case of recurrence of Grade 3 QTc prolongation, therapy should be withheld until recovery to less than or equal to Grade 1, then resumed at 250 mg once daily.  Permanently discontinue crizotinib therapy if Grade 3 QTc prolongation recurs or at any time during treatment if Grade 4 QTc prolongation develops.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568134, 'Cyclosporine', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568135, 'Dabrafenib', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568136, 'Danazol', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568137, 'Dapagliflozin', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568138, 'Darolutamide', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568139, 'Darunavir', 'Lopinavir', 'Moderate', 'Coadministration with lopinavir/ritonavir may decrease the plasma concentrations of darunavir, even in the presence of low-dose ritonavir as a pharmacokinetic booster.  The mechanism of interaction has not been described.', NULL, 'The appropriate dosage of darunavir when prescribed in combination with lopinavir/ritonavir has not been established.', NULL, 'The appropriate dosage of darunavir when prescribed in combination with lopinavir/ritonavir has not been established.  Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the use of darunavir with lopinavir/ritonavir is not recommended, with or without an additional low-dose of ritonavir.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568140, 'Dasatinib', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568141, 'Daunorubicin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568142, 'Doxorubicin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568143, 'Deferasirox', 'Lopinavir', 'Moderate', 'Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568144, 'Degarelix', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568145, 'Delavirdine', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568146, 'Desipramine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568147, 'Deutetrabenazine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568148, 'Dexamethasone', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568149, 'Didanosine', 'Lopinavir', 'Moderate', 'Since lopinavir-ritonavir oral solution must be taken with food, simultaneous administration with didanosine may interfere with the gastrointestinal absorption of didanosine, which should be taken on an empty stomach.', NULL, 'When prescribed in combination with lopinavir-ritonavir oral solution, didanosine should be administered on an empty stomach one hour before or two hours after lopinavir-ritonavir oral solution, which is to be taken with food.', NULL, 'When prescribed in combination with lopinavir-ritonavir oral solution, didanosine should be administered on an empty stomach one hour before or two hours after lopinavir-ritonavir oral solution, which is to be taken with food.  Lopinavir-ritonavir tablets can be administered simultaneously with didanosine without food.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568150, 'Digitoxin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568151, 'Digoxin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568152, 'Diltiazem', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568153, 'Disopyramide', 'Lopinavir', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568154, 'Valproic acid', 'Lopinavir', 'Moderate', 'Coadministration of protease inhibitors (e.g., lopinavir, ritonavir) with valproate may result in a reduction in the plasma concentrations and therapeutic effects of valproate.  The proposed mechanism may involve protease inhibitor induction of hepatic CYP450 enzymes, particularly glucuronosyltransferases, which increase metabolism of valproate.  This interaction has been reported with ritonavir and ritonavir-boosted lopinavir.', NULL, 'Caution is advised if valproate is used concomitantly with the protease inhibitors ritonavir and lopinavir.', NULL, 'Caution is advised if valproate is used concomitantly with the protease inhibitors ritonavir and lopinavir.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever protease inhibitors are added to or withdrawn from therapy with valproate.  Patients should be monitored for loss of seizure control.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568155, 'Dofetilide', 'Lopinavir', 'Major', 'Like other class III antiarrhythmic agents, dofetilide can cause dose-related QT interval prolongation.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.', NULL, 'Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568156, 'Dolasetron', 'Lopinavir', 'Major', 'Dolasetron can cause dose-related prolongation of the QT interval via its pharmacologically active metabolite, hydrodolasetron.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if dolasetron is used concomitantly with other agents that prolong the QT, PR and/or QRS interval, especially in the elderly and patients with known risk factors.', NULL, 'Caution is advised if dolasetron is used concomitantly with other agents that prolong the QT, PR and/or QRS interval, especially in the elderly and patients with known risk factors.  An ECG should be obtained in these patients before initiating dolasetron and periodically during treatment.  Patients should be advised to seek medical attention if they experience dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.  Dolasetron should be avoided in patients with complete heart block or at risk for complete heart block, unless they have an implanted pacemaker.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568157, 'Donepezil', 'Lopinavir', 'Moderate', 'Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.  Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568158, 'Doxepin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568159, 'Doxepin (topical)', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568160, 'Dronedarone', 'Lopinavir', 'Major', 'Dronedarone may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568161, 'Droperidol', 'Lopinavir', 'Major', 'The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death.  The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.  In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking droperidol with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents.', NULL, 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents.  The dosage of droperidol should be individualized and titrated to the desired effect.  Routine vital sign and ECG monitoring is recommended.  When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568162, 'Dulaglutide', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568163, 'Duvelisib', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568164, 'Echinacea', 'Lopinavir', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568165, 'Efavirenz', 'Lopinavir', 'Major', 'Coadministration with efavirenz may decrease the plasma concentrations of lopinavir, even in the presence of low-dose ritonavir as a pharmacokinetic booster.  The proposed mechanism is efavirenz induction of lopinavir metabolism via CYP450 3A4.', NULL, 'A dosage increase is recommended for lopinavir-ritonavir when used in combination with efavirenz.', NULL, 'A dosage increase is recommended for lopinavir-ritonavir when used in combination with efavirenz.  For adults, the dosage should be increased to 500 mg-125 mg (two 200 mg-50 mg tablets and one 100 mg-25 mg tablet) twice daily for the tablets and 533 mg-133 mg (6.5 mL) twice daily for the oral solution.  Lopinavir-ritonavir should not be administered as a once daily regimen in combination with efavirenz.  For pediatric patients 6 months to 18 years of age, the dosage should be increased to 300 mg-75 mg/m2 twice daily for the oral solution in both treatment-naive and treatment-experienced patients, not to exceed the recommended adult dosage of 533 mg-133 mg (6.5 mL) twice daily.  If weight-based dosing is preferred, the recommended dosage is 13 mg-3.25 mg/kg given twice daily for patients under 15 kg and 11 mg-2.75 mg/kg given twice daily for patients 15 kg to 45 kg.  Pediatric patients weighing more than 45 kg should receive the adult dosage of lopinavir-ritonavir.  Please consult the manufacturer''s product labeling for pediatric dosing of the tablet formulation.  Lopinavir-ritonavir should not be administered in combination with efavirenz in patients under 6 months of age due to the lack of clinical data.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568166, 'Elagolix', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568167, 'Eltrombopag', 'Lopinavir', 'Moderate', 'Coadministration with lopinavir-ritonavir has been shown to modestly decrease the plasma concentrations of eltrombopag.', NULL, 'No specific dosage adjustment is recommended when eltrombopag is used with lopinavir-ritonavir.', NULL, 'No specific dosage adjustment is recommended when eltrombopag is used with lopinavir-ritonavir.  However, platelet count should be more closely monitored following initiation or discontinuation of lopinavir-ritonavir therapy, and the eltrombopag dosage adjusted as necessary.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568168, 'Eluxadoline', 'Lopinavir', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline.  Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.', NULL, 'The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.', NULL, 'The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.  Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568169, 'Empagliflozin', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568170, 'Encorafenib', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568171, 'Entrectinib', 'Lopinavir', 'Moderate', 'Entrectinib may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib, after 1 month of treatment with entrectinib, and periodically during treatment as appropriate based on individual risk factors.  Some authorities suggest that if the QTc interval is between 481 to 500 msec at any time during treatment, entrectinib should be withheld until QTc is recovered to baseline at which time treatment at the same dose may be resumed (AU, UK).  If the QTc is greater than 500 msec, entrectinib should be withheld until the QTc interval recovers to baseline at which time the same dose may be resumed if factors that caused the QT prolongation are corrected.  However, if these factors are not identified and corrected, entrectinib should be resumed at a reduced dose.  Entrectinib should be permanently discontinued in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia such as torsade de pointes or polymorphic ventricular tachycardia.  Because hypokalemia and hypomagnesemia are risk factors for ventricular arrhythmias, electrolyte levels should also be obtained prior to and during treatment, and any abnormalities corrected as necessary.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568172, 'Enzalutamide', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568173, 'Epirubicin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568174, 'Eribulin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568175, 'Ertugliflozin', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568176, 'Erythromycin', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568177, 'Escitalopram', 'Lopinavir', 'Major', 'Escitalopram can cause dose-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568178, 'Eslicarbazepine', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568179, 'Esmolol', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568180, 'Etravirine', 'Lopinavir', 'Moderate', 'Coadministration with lopinavir-ritonavir may increase the plasma concentrations of etravirine.  The mechanism is inhibition of etravirine metabolism via CYP450 3A4.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with lopinavir-ritonavir.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with lopinavir-ritonavir.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568181, 'Exenatide', 'Lopinavir', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', NULL, 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568182, 'Ezogabine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568183, 'Famotidine', 'Lopinavir', 'Moderate', 'Famotidine may cause QTc prolongation.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568184, 'Fedratinib', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568185, 'Felbamate', 'Lopinavir', 'Moderate', 'Coadministration of lopinavir-ritonavir with inducers of CYP450 3A4 may decrease the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.  Clinical studies have shown that potent CYP450 3A4 inducers such as rifampin and phenytoin can significantly alter the plasma concentrations of lopinavir, possibly by overriding some of the inhibiting effects of ritonavir and enhancing the clearance of both lopinavir and ritonavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if lopinavir-ritonavir is prescribed with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568186, 'Felodipine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.', NULL, 'Caution is advised if lopinavir-ritonavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., calcium channel blockers) because lopinavir-ritonavir is a potent inhibitor of the isoenzyme.  The elderly as well as patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block associated with the use of lopinavir-ritonavir.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568187, 'Fingolimod', 'Lopinavir', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval.', NULL, 'Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.', NULL, 'Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).  Overnight continuous ECG monitoring after the first dose is recommended in accordance with the product labeling.  Fingolimod should not be given if baseline QTc interval is 500 msec or greater.  The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod.  Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568188, 'Flecainide', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568189, 'Fluconazole', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568190, 'Fluoxetine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568191, 'Fluphenazine', 'Lopinavir', 'Moderate', 'Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568192, 'Flutamide', 'Lopinavir', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1568193, 'Fluvoxamine', 'Lopinavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lopinavir, which is primarily metabolized by the isoenzyme.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', NULL, 'The magnitude and clinical significance of this interaction are unknown, particularly when in the presence of ritonavir as a pharmacokinetic booster.', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
